Prometheus Biosciences, Inc.

Disclaimer : Sections of this page are auto-generated by Artificial Intelligence and shall not be understood as Investment Advice
This page was updated : N/A. Premium customers can update this page on demand.
Invite a Friend
Business Overview

N/A

Yahoo - Business Overview

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially ...

Website
#ibd #mab #prometheus #pra #pr #biosciences #inflammatory #cytokine #diseases #anti #United States #Healthcare

Risk Rating (Yahoo)

10

ESG Score (Yahoo)

N/A

Market Cap (USD)

9.50 B

AI Rank (finclout)

517

Competitors
Flags & Key Risks
Negative profit margins Negative EV to Ebitda Negative Return on Equity Insiders are selling Clinical stage company Negative Revenue Trend Pre-market negative on higher volumes
Themes
Biotechnology Therapeutics Inflammatory Bowel Diseases Clinical Trials Collaborations

SWOT Analysis

Strengths

N/A  

Weaknesses

N/A                                                                                                                                                                                                                                                                                                      

Opportunities

N/A                                                                                                                                                                                                                                                                                                      

Threats

N/A                                                                                                                                                                                                                                                                                                      

stock price by TradingView

Thesis for Prometheus Biosciences, Inc.

Bullish

N/A ...

Neutral

N/ ...

Bearish

N/ ...

News Coverage

No research found for
Offcanvas top
Placeholder
Offcanvas left
Placeholder

 

 

 

 

 

Offcanvas bottom
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.